Announcements Trials
Browse Landscape

Phase

Phase 2 5

Status

Unknown 5Recruiting 4Not yet recruiting 4Active not recruiting 1

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 5

Conditions

Colorectal Neoplasms 17Stomach Neoplasms 5Rectal Neoplasms 2Colonic Neoplasms 2Advanced Colorectal Carcinoma 2Unresectable Metastatic Colorectal Cancer 1TAS 102 1Sarcoma 1Patients With Advanced Metastatic Colorectal Cancer 1Pancreatic Neoplasms 1Metastasis Colorectal Cancer 1Locally Advanced Rectal Cancer 1HER2-positive Gastric Cancer 1Fruquintinib 1Esophageal Squamous Cell Carcinoma 1Colorectal Adenocarcinoma 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Biliary Tract Adenocarcinoma 1Advanced Pancreatic Carcinoma 1

Interventions

Oxaliplatin 81S 1 (combination) 55Capecitabine 44apatinib 32Paclitaxel 32Docetaxel 32Irinotecan 27Fluorouracil 22Drug Therapy 21sintilimab 20Cisplatin 20Leucovorin 16Hyperthermic Intraperitoneal Chemotherapy 13XELOX 12Surgical Procedures, Operative 12camrelizumab 10Trastuzumab 10titanium silicide 9Tegafur 9Nivolumab 9Neoadjuvant Therapy 9pembrolizumab 8Laparoscopy 8Gastrectomy 8Folfox protocol 7Chemotherapy, Adjuvant 7toripalimab 6tislelizumab 6Ramucirumab 6Gastroscopy 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Unknown × Stomach Neoplasms × HMPL-013 × Clear all
NCT05625737 2024-09-19

Fruquintinib Combined with Sintilimab As Second-line Therapy for Gastric or Gastro-esophageal Junction Adenocarcinoma

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Phase 2 Unknown
29 enrolled
Gastrointestinal

Stomach Neoplasms

NCT05122091 2024-02-26

Fruquintinib Plus SOX as Neoadjuvant Therapy for Locally Advanced Gastric Adenocarcinoma

Guangxi Medical University

Phase 2 Unknown
53 enrolled
Gastrointestinal

Stomach Neoplasms

NCT05795296 2023-08-30

Efficacy and Safety of Fruquintinib With Sintilimab as First-line Therapy in Gastric Cancer

RenJi Hospital

Phase 2 Unknown
30 enrolled
Gastrointestinal

Stomach Neoplasms

NCT05643677 2022-12-09

Fruquintinib Plus Irinotecan in the Treatment of Advanced Gastric Cancer

Fujian Medical University

Phase 2 Unknown
47 enrolled
Gastrointestinal

Stomach Neoplasms

NCT05241899 2022-02-16

A Phase II Clinical Study of Fruquintinib Combined With RC48 in the Treatment of Previously Treated HER2-positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (G/GEJ) Cancer

The First Affiliated Hospital of Zhengzhou University

Phase 2 Unknown
56 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡